(Q50038355)

23 February 2018

title

Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity. (English)

1 reference

23 February 2018

1 reference

Salmonella typhi

1 reference

So Jung An

1

1 reference

23 February 2018

Yeon Kyung Yoon

2

1 reference

23 February 2018

Sudeep Kothari

3

1 reference

23 February 2018

Neha Kothari

4

1 reference

23 February 2018

Jeong Ah Kim

5

1 reference

23 February 2018

Eugene Lee

6

1 reference

23 February 2018

Deok Ryun Kim

7

1 reference

23 February 2018

Tai Hyun Park

8

1 reference

23 February 2018

Greg W Smith

9

1 reference

23 February 2018

Rodney Carbis

10

1 reference

23 February 2018

language of work or name

English

0 references

publication date

16 August 2011

1 reference

23 February 2018

published in

Vaccine

1 reference

23 February 2018

volume

29

1 reference

23 February 2018

issue

44

1 reference

23 February 2018

page(s)

7618-7623

1 reference

23 February 2018

Population impact of Vi capsular polysaccharide vaccine.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.019

Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.019

Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.019

Thymus-independent and thymus-dependent responses to polysaccharide antigens

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.019

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.019

inferred from DOI database lookup

7 January 2021

based on heuristic

Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.019

Optimization of Vi capsular polysaccharide production during growth of Salmonella enterica serotype Typhi Ty2 in a bioreactor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.019

Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.019

Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.019

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.019

Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.019

The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.019

Glycoprotein conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.019

Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.019

Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.019

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.08.019

1 reference

23 February 2018

1 reference

23 February 2018